Compare PRAX & KMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | KMX |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.6B |
| IPO Year | 2020 | 2002 |
| Metric | PRAX | KMX |
|---|---|---|
| Price | $254.33 | $51.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 20 |
| Target Price | ★ $650.00 | $63.77 |
| AVG Volume (30 Days) | 481.4K | ★ 2.9M |
| Earning Date | 11-04-2026 | 09-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.47 |
| Revenue | N/A | ★ $25,881,131,000.00 |
| Revenue This Year | N/A | $4.58 |
| Revenue Next Year | $39,256.17 | $1.26 |
| P/E Ratio | ★ N/A | $21.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $154.46 | $30.26 |
| 52 Week High | $392.70 | $65.28 |
| Indicator | PRAX | KMX |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 41.29 |
| Support Level | $237.78 | $49.21 |
| Resistance Level | $356.02 | $54.22 |
| Average True Range (ATR) | 12.32 | 1.97 |
| MACD | 2.23 | 0.10 |
| Stochastic Oscillator | 32.24 | 31.85 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
CarMax sells, finances, and services used and new cars through a chain of over 255 retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 80% of fiscal 2026 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2026, the company retailed and wholesaled 780,684 and 538,203 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US, but still estimates that it had only about 3.6% US market share of vehicles zero to 10 years old in calendar 2025. CarMax is based in Richmond, Virginia.